Literature DB >> 4598244

Combination chemotherapy with adriamycin (NSC-123127) in metastatic mammary carcinoma.

C Brambilla, M De Lena, G Bonadonna.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4598244

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  6 in total

1.  Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy.

Authors:  Jörg Schilling; Christian M Kurbacher; Claus Hanusch; Steffi Busch; Martin Holländer; Janine Kreiss-Sender; Daniela Rezek; Elisa Flahaut; Meinolf Karthaus
Journal:  Breast Care (Basel)       Date:  2021-05-25       Impact factor: 2.268

2.  Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.

Authors:  M De Lena; R Zucali; G Viganotti; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

3.  Sequential combination chemotherapy in advanced breast cancer.

Authors:  C Brambilla; P Valagussa; G Bonadonna
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

4.  [Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)].

Authors:  K Höffken; S Seeber; W R Boecker; C G Schmidt
Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol       Date:  1976-06-15

5.  Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination.

Authors:  R D Rubens; R K Knight; J L Hayward
Journal:  Br J Cancer       Date:  1975-12       Impact factor: 7.640

Review 6.  Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy.

Authors:  Bruce D Keith
Journal:  BMC Cancer       Date:  2008-03-28       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.